PALSONIFY (Paltusotine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

PALSONIFY (Paltusotine Hydrochloride) by Crinetics Pharmaceuticals: FDA Orange Book core substance LOE 2041-09-07 (last listed 2044-03-25), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $24,165 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCrinetics Pharmaceuticals
FDA Application & PathwayN219070 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-09-07
Last Listed Patent or Exclusivity Date2044-03-25
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($24,165 intro WAC)